AbbVie - Coronavirus (COVID-19) Response

AbbVie is collaborating with global health authorities and institutions, including the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), World Health Organization (WHO), among others, to evaluate any potential antiviral activity as well as efficacy and safety of KALETRA® /Aluvia (lopinavir/ritonavir)* against COVID-19. We’ve also joined the Innovative Medicines Initiative to support research and discovery of targeted medicines against COVID-19.

AbbVie has supplied KALETRA/Aluvia as an experimental option for the treatment of COVID-19 to multiple countries that have immediate patient needs due to the outbreak, including donating product to the Chinese government in the early days of their fight against the virus.
 
While helping respond to the coronavirus crisis is a high priority for our company, we are committed to protecting the supply of KALETRA/Aluvia for existing patients.